A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C

NCT01271790 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

245

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C, Chronic

Interventions

DRUG: Tegobuvir (GS-9190)
DRUG: GS-9451
BIOLOGICAL: Pegasys®
DRUG: Copegus®
DRUG: GS-9451
DRUG: Tegobuvir placebo
BIOLOGICAL: Pegasys®
DRUG: Copegus®
DRUG: Tegobuvir placebo
DRUG: GS-9451 placebo
BIOLOGICAL: Pegasys®
DRUG: Copegus®

Sponsor

Gilead Sciences